Belimumab Dose Spacing May Be an Option for Selected Patients With SLE in Sustained Remission

As reported on MedScape, gradually extending the interval between belimumab doses may allow carefully selected patients with systemic lupus erythematosus (SLE) in long-term remission to reduce treatment exposure (and in…

Continue Reading Belimumab Dose Spacing May Be an Option for Selected Patients With SLE in Sustained Remission

Insights into Gazyva as a Treatment for Lupus/SLE

A recent article from Inside Precision Medicine states: For decades, systemic lupus erythematosus (SLE) has resisted tidy solutions, a shapeshifting autoimmune disease that crosses into different organ systems, flares without…

Continue Reading Insights into Gazyva as a Treatment for Lupus/SLE

CRISPR Therapeutics Shares Promising Updates on Zugo-cel in Autoimmune and Oncology Trials

CRISPR Therapeutics has announced encouraging early results for zugocaptagene geleucel (zugo-cel), its investigational allogeneic CAR T therapy targeting CD19, in both autoimmune diseases and hematologic malignancies. Autoimmune Disease Progress In…

Continue Reading CRISPR Therapeutics Shares Promising Updates on Zugo-cel in Autoimmune and Oncology Trials
May is Lupus Awareness Month!
https://pixabay.com/en/flower-rain-macro-detail-purple-641401/

May is Lupus Awareness Month!

Also known as systemic lupus erythematosus (SLE), lupus is a chronic autoimmune disorder in which the immune system mistakenly attacks different parts of the body such as the joints, kidneys,…

Continue Reading May is Lupus Awareness Month!
ICYMI: FDA Clears CNTY-101 IND Application for Lupus
source: shutterstock.com

ICYMI: FDA Clears CNTY-101 IND Application for Lupus

A drug cannot be transported or distributed across state lines until its marketing application has been approved/cleared, so getting this clearance is crucial for many drug developers and physicians who…

Continue Reading ICYMI: FDA Clears CNTY-101 IND Application for Lupus